Author Archives: Richard Daverman

invoX acquires bispecific firm F-Star for $161m

invoX Pharma, a Sino Biopharm subsidiary, will pay $161 million to acquire F-Star, a Cambridge, UK clinical stage company developing bispecific drugs for immunotherapies. F-star’s platform technology pioneers the use of tetravalent (2+2) bispecific antibodies. These antibodies target two different antigens and are paired with a unique set of pharmacology agents to activate an immune reaction in the tumor microenvironment. F-Star has four candidates in clinical trials, three from its tetravalent platform and one next-gen STING agonist. invoX, located in…

China’s I-Mab allegedly seeking asset or company sale

Shanghai-based I-Mab is in talks with global drugmakers about a potential sale of the whole company or its oncological assets, according to a Bloomberg article. The Bloomberg article claims US and EU pharmas were interested in I-Mab, given its portfolio of 10 clinical stage oncology antibodies plus access to the world’s second largest pharmaceutical market. Bloomberg noted that I-Mab has lost three-fourths of its market value since the prices for pharmaceutical companies peaked in June 2021. When it announced its…

China: US auditors can examine US-listed companies in policy change

China plans to furnish US auditors with full access to the financial records of China companies that have US listings. The change seems to solve a looming crisis between the two countries, as the US is currently threatening to de-list all China companies that closed their financial documents to US auditors. The revised regulation will allow scrutiny of China-based companies’ books, while detailing how to handle national security information, which will remain protected. The new policy was announced earlier this…